CN113995788B - Liver protection composition and preparation process thereof - Google Patents
Liver protection composition and preparation process thereof Download PDFInfo
- Publication number
- CN113995788B CN113995788B CN202010740135.7A CN202010740135A CN113995788B CN 113995788 B CN113995788 B CN 113995788B CN 202010740135 A CN202010740135 A CN 202010740135A CN 113995788 B CN113995788 B CN 113995788B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- weight
- fructus aurantii
- distilled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title description 36
- 210000004185 liver Anatomy 0.000 title description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 77
- 239000003814 drug Substances 0.000 claims abstract description 44
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 16
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 7
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 7
- 244000274050 Platycodon grandiflorum Species 0.000 claims abstract description 6
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims abstract description 6
- 244000197580 Poria cocos Species 0.000 claims abstract description 6
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 6
- 241000951473 Schizonepeta Species 0.000 claims abstract description 6
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 6
- 235000011477 liquorice Nutrition 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims description 45
- 239000000243 solution Substances 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 238000004821 distillation Methods 0.000 claims description 27
- 239000000341 volatile oil Substances 0.000 claims description 22
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 241001180876 Saposhnikovia Species 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 208000029028 brain injury Diseases 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 244000183685 Citrus aurantium Species 0.000 claims 1
- 235000007716 Citrus aurantium Nutrition 0.000 claims 1
- 241000229179 Ledebouriella Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 51
- 210000005013 brain tissue Anatomy 0.000 abstract description 17
- 230000035622 drinking Effects 0.000 abstract description 13
- 230000006378 damage Effects 0.000 abstract description 8
- 208000014674 injury Diseases 0.000 abstract description 5
- 208000027418 Wounds and injury Diseases 0.000 abstract description 4
- 230000004149 ethanol metabolism Effects 0.000 abstract description 4
- 230000036542 oxidative stress Effects 0.000 abstract description 3
- 206010067125 Liver injury Diseases 0.000 abstract description 2
- 231100000753 hepatic injury Toxicity 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 28
- 239000008187 granular material Substances 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 17
- 238000001914 filtration Methods 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 208000007848 Alcoholism Diseases 0.000 description 9
- 201000007930 alcohol dependence Diseases 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000002075 anti-alcohol Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000020927 12-h fasting Nutrition 0.000 description 1
- 241001254604 Angelica pubescens Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 241000212322 Levisticum officinale Species 0.000 description 1
- 241000244365 Ligusticum sinense Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000570 acute poisoning Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000001645 levisticum officinale Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 208000010540 rapid respiration Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for preventing or treating side effects after drinking. The traditional Chinese medicine composition is mainly prepared from notopterygium root, radix angelicae pubescentis, poria cocos, radix sileris, schizonepeta, ligusticum wallichii, platycodon grandiflorum, radix bupleuri, radix peucedani, fructus aurantii and liquorice. The traditional Chinese medicine composition can relieve oxidative stress injury of alcohol to brain tissues, so as to protect the brain tissues; can also accelerate ethanol metabolism by increasing ADH activity, increase SOD activity, and reduce liver injury.
Description
Technical Field
The invention relates to a composition and a preparation method thereof, in particular to a composition for protecting liver and a preparation process thereof, more particularly relates to a composition with the function of preventing or treating side effects after drinking and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines.
Background
Alcoholism commonly known as drunk refers to an abnormal state of body function of a patient after drinking a large amount of alcohol (ethanol) at a time, and has the most serious damage to a nervous system and liver.
The traditional Chinese medicine considers that the alcoholic flavor is spicy and sweet and warm, the five elements belong to the shapes of wind-fire, strong dispersing power, large channeling power, and can promote qi and blood, strengthen yang and transform qi, and dispel yin. The wine is often used as a blood activating and stasis resolving medicine for treating internal and external injuries such as traumatic injury, blood stasis and swelling pain, etc. however, the wine is good in running and easy to run, has strong opening and discharging force, and simultaneously is too much to cause qi and blood to run, so that qi consumption damages blood, yin fluid is damaged, and discomfort can occur.
The clinical symptoms after drinking in Chinese medicine are mainly of the following types:
(1) The syndrome of excess in the exterior and interior manifests as headache, body pain, nausea and vomiting and rapid respiration; (2) The exterior excess and interior heat syndrome manifests as headache, heavy body, body pain, dysphoria and inability to sleep; (3) The exterior deficiency and interior heat syndrome manifests as profuse sweat, excitement, multiple language and shortness of breath; (4) Deficiency of the interior heat manifested as excessive sweating, debilitation, dry mouth, thirst, fatigue or dizziness and palpitation; (5) The symptoms of qi and yin impairment are mental confusion, cold limbs, incontinence of urine and feces, wet and cold body, and rapid pulse (shock after alcoholism or early shock manifestation); (6) Spleen deficiency and damp-weight syndrome manifested by distention and fullness, abdominal distention, loose stool, and no desire to eat or beer belly; (7) Blood deficiency with wind-generating syndrome manifested as paralysis of hands and feet, tremor of limbs, easy spasm, emaciation, anorexia, no desire to eat or drink, good drinking, and more excitation.
Wine is good at dispersing and moving in five elements such as wind and fire, and has unexpected effects because of its qi movement such as wind and heat such as fire, easy consumption of qi to hurt blood, and the need of bitter and cool nature and qi and yin tonifying.
The anti-alcohol effect of the modified Jingfang antiphlogistic powder on mice with acute alcoholism (Tong Yan and the like, journal of Chinese experimental prescriptions, 17 (21), 221-223) is recorded in the text, the modified Jingfang antiphlogistic powder (10 g of schizonepeta, 10g of divaricate saposhnikovia root, 20g of kudzuvine flower, 12g of notopterygium root, 12g of pubescent angelica root, 20g of poria cocos, 12g of szechuan lovage rhizome and 3g of honey-fried licorice root) can reduce the drunk rate before drinking, prolong the drunk latency, shorten the drunk time after drinking and reduce the death rate, and has the remarkable effects of dispelling alcohol and promoting the awakening.
Disclosure of Invention
The invention mainly aims to provide a traditional Chinese medicine composition with the effect of preventing or treating side effects after drinking, which is mainly prepared from notopterygium root, radix angelicae pubescentis, poria cocos, radix sileris, schizonepeta, ligusticum wallichii, platycodon grandiflorum, radix bupleuri, radix peucedani, fructus aurantii and liquorice.
The invention is a further development of the application of the Jingfeng granule based on the existing product, the new application of the Jingfeng granule for dispelling the effects of alcohol is derived from the feedback of patients after use, and the patients with wind-cold common cold need to drink alcohol for special reasons after taking the Jingfeng granule medicine during illness, as a result, the drinking rate can be obviously reduced after taking the Jingfeng granule medicine, and the drunk time can be obviously shortened after drinking, and based on the clinical use feedback, the inventor carries out the development of the new application of dispelling the effects of alcohol on Jingfeng granule and the components thereof and treating the side effects after drinking.
The invention aims at providing an application of a traditional Chinese medicine composition prepared from notopterygium root, radix angelicae pubescentis, poria cocos, radix saposhnikoviae, schizonepeta, ligusticum wallichii, platycodon grandiflorum, radix bupleuri, radix peucedani, fructus aurantii and liquorice in protecting liver.
The traditional Chinese medicine composition is mainly prepared from the following raw materials:
preferably, the traditional Chinese medicine composition is mainly prepared from the following raw materials:
in one of the further preferable schemes, the traditional Chinese medicine composition is mainly prepared from the following raw materials:
in a second preferred scheme, the traditional Chinese medicine composition is mainly prepared from the following raw materials:
the second purpose of the invention is to provide the specific application of the traditional Chinese medicine composition, which mainly comprises the following steps:
the application of the traditional Chinese medicine composition in preparing medicines for preventing or treating side effects after drinking wine;
side effects after drinking include, but are not limited to, loose stool, stomach distention, nausea, vomiting, headache, dizziness, palpitations;
the application of the traditional Chinese medicine composition in preparing medicines for preventing, treating and/or relieving alcoholic liver injury and brain injury. The invention also aims to provide a preparation method of the traditional Chinese medicine composition, which mainly comprises the following steps:
step A: extracting volatile oil from herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong and fructus Aurantii by distillation, and collecting the residue after distillation and distilled rhizoma Ligustici Chuanxiong and fructus Aurantii water solution;
and (B) step (B): c, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii into 10-40% ethanol solution for later use;
step C: mixing Poria, distilled rhizoma Ligustici Chuanxiong and fructus Aurantii residue obtained in step A, percolating with ethanol solution obtained in step B, and collecting percolate;
step D: decocting bupleuri radix, radix Platycodi, glycyrrhrizae radix, distilled herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis and radix Peucedani residue in water, and concentrating the decoction;
step E: mixing the percolate obtained in the step C and the decoction obtained in the step D, concentrating, and adding the volatile oil obtained in the step A to obtain the final product.
Preferably, the preparation method mainly comprises the following steps:
step A: extracting volatile oil from herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong and fructus Aurantii by distillation, and collecting the residue after distillation and distilled rhizoma Ligustici Chuanxiong and fructus Aurantii water solution;
and (B) step (B): c, preparing the distilled Ligusticum wallichii and fructus aurantii aqueous solution obtained in the step A into a 15-30% ethanol solution for later use;
step C: mixing Poria, distilled rhizoma Ligustici Chuanxiong and fructus Aurantii residue obtained in step A, percolating with ethanol solution obtained in step B, and collecting percolate;
step D: decocting bupleuri radix, radix Platycodi, glycyrrhrizae radix, and residues of distilled herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis and radix Peucedani in water, and concentrating the decoction to obtain soft extract;
step E: mixing the percolate obtained in step C and the soft extract obtained in step D, concentrating to obtain fluid extract, and adding the volatile oil obtained in step A.
Further preferably, the preparation method mainly comprises the following steps:
step A: extracting volatile oil from herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong and fructus Aurantii by distillation, and collecting the residue after distillation and distilled rhizoma Ligustici Chuanxiong and fructus Aurantii water solution;
and (B) step (B): c, preparing the distilled Ligusticum wallichii and fructus aurantii aqueous solution obtained in the step A into 25% ethanol solution for later use;
step C: mixing Poria, distilled rhizoma Ligustici Chuanxiong and fructus Aurantii residue obtained in step A, percolating with ethanol solution obtained in step B, and collecting percolate;
step D: decocting bupleuri radix, radix Platycodi, glycyrrhrizae radix, and residues of distilled herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis and radix Peucedani in water, and concentrating the decoction to obtain soft extract;
step E: mixing the percolate obtained in step C and the soft extract obtained in step D, concentrating to obtain fluid extract, and adding the volatile oil obtained in step A.
The fourth purpose of the invention is to provide a traditional Chinese medicine preparation containing the traditional Chinese medicine composition, wherein the traditional Chinese medicine preparation is a clinically acceptable oral preparation;
preferably, the clinically acceptable oral preparation is one or more of a pill, a capsule, a tablet, a granule or a liquid oral preparation;
even more preferably, the oral formulation is a granule.
Compared with the prior art, the invention has the remarkable technical effects that:
1. the traditional Chinese medicine composition can raise the SOD and GSH levels of brain tissues and reduce the MDA level; can relieve oxidative stress injury of alcohol to brain tissue, thereby protecting brain tissue.
2. The traditional Chinese medicine composition has obvious anti-alcohol effect, can accelerate ethanol metabolism by increasing ADH activity, can also increase SOD activity, and reduces damage to liver.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
Example 1 preparation of granules
Prescription:
the preparation method comprises the following steps:
step A: extracting volatile oil from herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii by distillation respectively, and collecting the residue after distillation and the water solution of rhizoma Ligustici Chuanxiong and fructus Aurantii after distillation;
and (B) step (B): c, preparing the distilled Ligusticum wallichii and fructus aurantii aqueous solution obtained in the step A into 25% ethanol solution for later use;
step C: mixing Poria, distilled rhizoma Ligustici Chuanxiong and fructus Aurantii residue obtained in step A, percolating with ethanol solution obtained in step B, and collecting percolate;
step D: decocting bupleuri radix, radix Platycodi, glycyrrhrizae radix, distilled herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, and radix Peucedani residue in water for 1.5 hr twice, mixing decoctions, filtering, and concentrating into soft extract;
step E: mixing the percolate obtained in step C and the soft extract obtained in step D, standing, filtering, concentrating to obtain fluid extract, adding sucrose, mixing, granulating, drying, adding the volatile oil obtained in step A, and mixing.
Example 2 preparation of granules
Prescription:
the preparation method is the same as in example 1.
Example 3 preparation of granules
Prescription:
the preparation method is the same as in example 1.
Example 4 preparation of oral liquid
Prescription:
the preparation method comprises the following steps:
step A: extracting volatile oil from herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii by distillation respectively, and collecting the residue after distillation and the water solution of rhizoma Ligustici Chuanxiong and fructus Aurantii after distillation;
and (B) step (B): c, preparing the distilled Ligusticum wallichii and fructus aurantii aqueous solution obtained in the step A into 10% ethanol solution for later use;
step C: mixing Poria, distilled rhizoma Ligustici Chuanxiong and fructus Aurantii residue obtained in step A, percolating with ethanol solution obtained in step B, and collecting percolate;
step D: decocting bupleuri radix, radix Platycodi, glycyrrhrizae radix, distilled herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, and radix Peucedani residue in water for 1.5 hr twice, mixing decoctions, filtering, and concentrating into soft extract;
step E: mixing the percolate obtained in the step C and the thick paste obtained in the step D, standing, filtering, concentrating into fluid extract, adding appropriate amount of sucrose, mixing, adding the volatile oil obtained in the step A, mixing, and adding water to 1000 ml.
EXAMPLE 5 syrup preparation
Prescription:
the preparation method comprises the following steps:
step A: extracting volatile oil from herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii by distillation respectively, and collecting the residue after distillation and the water solution of rhizoma Ligustici Chuanxiong and fructus Aurantii after distillation;
and (B) step (B): c, preparing the distilled Ligusticum wallichii and fructus aurantii aqueous solution obtained in the step A into 40% ethanol solution for later use;
step C: mixing Poria, distilled rhizoma Ligustici Chuanxiong and fructus Aurantii residue obtained in step A, percolating with ethanol solution obtained in step B, and collecting percolate;
step D: decocting bupleuri radix, radix Platycodi, glycyrrhrizae radix, distilled herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, and radix Peucedani residue in water for 1.5 hr twice, mixing decoctions, filtering, and concentrating into soft extract;
step E: mixing the percolate obtained in the step C and the thick paste obtained in the step D, standing, filtering, concentrating into fluid extract, adding appropriate amount of sucrose, mixing, adding 500ml of the volatile oil and the monosaccharide syrup obtained in the step A, mixing, standing, filtering, and adding water to 1000 ml.
Example 6 tablet preparation
Prescription:
the preparation method comprises the following steps:
step A: extracting volatile oil from herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii by distillation respectively, and collecting the residue after distillation and the water solution of rhizoma Ligustici Chuanxiong and fructus Aurantii after distillation;
and (B) step (B): c, preparing the distilled Ligusticum wallichii and fructus aurantii aqueous solution obtained in the step A into a 15% ethanol solution for later use;
step C: mixing Poria, distilled rhizoma Ligustici Chuanxiong and fructus Aurantii residue obtained in step A, percolating with ethanol solution obtained in step B, and collecting percolate;
step D: decocting bupleuri radix, radix Platycodi, glycyrrhrizae radix, distilled herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, and radix Peucedani residue in water for 1.5 hr twice, mixing decoctions, filtering, and concentrating into soft extract;
step E: mixing the percolate obtained in step C and the soft extract obtained in step D, standing, filtering, concentrating to obtain fluid extract, adding appropriate amount of sucrose, mixing, granulating, drying, adding the volatile oil obtained in step A, mixing, granulating, adding appropriate amount of adjuvant, mixing, and tabletting.
Example 7 preparation of capsules
Prescription:
step A: extracting volatile oil from herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii by distillation respectively, and collecting the residue after distillation and the water solution of rhizoma Ligustici Chuanxiong and fructus Aurantii after distillation;
and (B) step (B): c, preparing the distilled Ligusticum wallichii and fructus aurantii aqueous solution obtained in the step A into 30% ethanol solution for later use;
step C: mixing Poria, distilled rhizoma Ligustici Chuanxiong and fructus Aurantii residue obtained in step A, percolating with ethanol solution obtained in step B, and collecting percolate;
step D: decocting bupleuri radix, radix Platycodi, glycyrrhrizae radix, distilled herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, and radix Peucedani residue in water for 1.5 hr twice, mixing decoctions, filtering, and concentrating into soft extract;
step E: mixing the percolate obtained in step C and the soft extract obtained in step D, standing, filtering, concentrating to obtain fluid extract, adding sucrose, mixing, granulating, drying, adding the volatile oil obtained in step A, mixing, granulating, drying, pulverizing, and making into capsule.
Example 8 preparation of pills
Prescription:
the preparation method comprises the following steps:
step A: extracting volatile oil from herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii by distillation respectively, and collecting the residue after distillation and the water solution of rhizoma Ligustici Chuanxiong and fructus Aurantii after distillation;
and (B) step (B): c, preparing the distilled Ligusticum wallichii and fructus aurantii aqueous solution obtained in the step A into 25% ethanol solution for later use;
step C: mixing Poria, distilled rhizoma Ligustici Chuanxiong and fructus Aurantii residue obtained in step A, percolating with ethanol solution obtained in step B, and collecting percolate;
step D: decocting bupleuri radix, radix Platycodi, glycyrrhrizae radix, distilled herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, and radix Peucedani residue in water for 1.5 hr twice, mixing decoctions, filtering, and concentrating into soft extract;
step E: mixing the percolate obtained in the step C and the thick paste obtained in the step D, standing, filtering, concentrating into clear paste, adding a proper amount of sucrose, mixing uniformly, granulating, drying, adding the volatile oil obtained in the step A, mixing uniformly, drying, crushing, sieving, adding 40-60 g of refined honey, making pills with a proper amount of water, and drying to obtain the traditional Chinese medicine.
Comparative example 1 preparation of granules
Prescription:
the preparation method comprises the following steps:
step A: extracting volatile oil from herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, and rhizoma Ligustici Chuanxiong by distillation respectively, and collecting the residue and water solution;
and (B) step (B): preparing the distilled Ligusticum chuanxiong Hort aqueous solution obtained in the step A into 25% ethanol solution for later use;
step C: mixing Poria and the distilled rhizoma Ligustici Chuanxiong residue obtained in step A, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting flos Puerariae Lobatae, glycyrrhrizae radix, distilled herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, and radix Peucedani residue in water for 1.5 hr twice, mixing decoctions, filtering, and concentrating into soft extract;
step E: mixing the percolate obtained in step C and the soft extract obtained in step D, standing, filtering, concentrating to obtain fluid extract, adding sucrose, mixing, granulating, drying, adding the volatile oil obtained in step A, and mixing.
Comparative example 2 preparation of oral liquid
Prescription:
the preparation method comprises the following steps:
decocting the above materials in water for 3 times, mixing the decoctions, and concentrating to 1.62 g/ml.
2. Pharmacological experiments
In order to verify the efficacy of the traditional Chinese medicine composition in aspects of dispelling the effects of alcohol and the like, the inventor conducts related pharmacodynamic test research. The medicine selected by the following pharmacodynamic tests is a representative formula and a medicine obtained by the preparation method of the invention; the inventor also carries out pharmacodynamic experiments on other formulas and medicines obtained by the preparation method, and experimental results show that the medicines obtained by the other formulas and the preparation method have the same or similar effects, but are not exhaustive because of space limitation; in addition, the following pharmacodynamic experiments only exemplify a partially representative animal model to verify the efficacy of the present invention.
The inventor has noted that the following experimental studies are conducted on the basis of the safety of the drug proved by the acute toxicity test and the long-term toxicity test, and the administration dosage in the experimental study is within the safe dosage range.
(one) Effect of the composition of the present invention on the antioxidant effect of brain tissue of mice suffering from acute alcoholism
1 Material
1.1 animals:
kunming mice, SPF grade, 18-22 g, experimental animal license number: SYXK 2018 0008, supplied by runan pharmaceutical group inc, was adapted for one week prior to the experiment.
1.2 drugs, agents
1.2.1 medicaments
Granules obtained in examples 1 and 2 of the present invention;
granules obtained in comparative examples 1 and 2.
1.2.3 mouse dosage
Example 1 granules: 2.925g/kg (high dose), 5.85g/kg (medium dose), 11.7g/kg (low dose);
example 2 granules: 5.85g/kg;
comparative example 1 granules: 5.85g/kg;
comparative example 2 oral liquid: 10ml/kg.
2. Experimental procedure
2.1 method of Forming mold
80 mice were randomly assigned to a blank group, a model group, three dose groups of example 1 (high, medium, low), example 2 group, comparative example 1 group, comparative example 2 group, and 10 mice per group.
The blank group and the model group are subjected to gastric lavage and distilled water is respectively subjected to gastric lavage and corresponding medicines are respectively subjected to 1 time/day for the other groups of mice; after 1h of administration, the mice in each group except the blank group are uniformly and twice subjected to gastric lavage for 30 days, wherein 0.3ml of 56-degree Beijing red star Erguotou white spirit is administered.
2.2 detection index
2.2.1 fasting for 12h after the last administration, the body weight of the mice was measured, brain tissue was taken and weighed, and brain index was calculated.
2.2.2 preparation of tissue homogenate from brain tissue, taking supernatant, measuring and calculating the content of MDA and GSH and SOD activity of brain tissue according to the instruction of the kit.
2.3 statistical treatment
Statistical analysis of the obtained data using SPSS22.0 software for metering the dataThe comparison is shown using one-way analysis of variance. With P<A difference of 0.05 is statistically significant.
3. Results and conclusions
3.1 Effect of the Chinese medicinal composition of the present invention on the brain index of alcoholism mice
Compared with the blank group, the brain index of the mice in the model group is obviously increased, and the difference has statistical significance (P < 0.01); compared with the model group, the brain index of the mice in each administration group is obviously reduced, and the difference has statistical significance (P < 0.01); the brain index was significantly higher in the comparative examples 1, 2 compared to the low dose group of example 1, the difference being statistically significant (P < 0.05).
Table 1 brain index comparison of mice in each groupn＝10)
Note that: in contrast to the blank set of the samples, @ P＜0.05， * P＜0.01；
in contrast to the set of models, △ P＜0.05， # P＜0.01；
in contrast to the low dose group of example 1, & P＜0.05。
3.2 Effect of the Chinese medicinal composition of the present invention on the brain tissue SOD, MDA, GSH of alcoholism mice
Compared with a blank group, the GSH content and SOD activity of the model group are obviously reduced, the MDA content is obviously increased, and the difference has statistical significance (P < 0.01); compared with the model group, the SOD activity and GSH content of each administration group are obviously increased, the MDA content is obviously reduced, and the difference has statistical significance (P is less than 0.05 and P is less than 0.01); compared with the low dose group of example 1, the GSH content and SOD activity of the comparative examples 1 and 2 are lower, the MDA content is higher, and the difference is statistically significant (P <0.05, P < 0.01).
TABLE 2 SOD activity, MDA and GSH content of mice brain tissue of each groupn＝10)
Note that: in contrast to the blank set of the samples, @ P＜0.05， * P＜0.01；
in contrast to the set of models, △ P＜0.05， # P＜0.01；
in contrast to the low dose group of example 1, & P＜0.05， ￥ P＜0.01。
research shows that after the concentration of alcohol in brain tissue is increased, a great amount of peroxidation products such as oxygen free radicals, active oxygen and the like are generated by the metabolism of alcohol in brain tissue, and simultaneously lipid peroxidation reaction of an organism can be promoted, so that the brain tissue is further damaged.
The experimental result shows that after the treatment of the traditional Chinese medicine composition provided by the invention, the SOD and GSH levels of brain tissues are increased, and the MDA levels are reduced, so that the traditional Chinese medicine composition provided by the invention can relieve oxidative stress injury of alcohol to the brain tissues, thereby protecting the brain tissues.
(II) the Chinese medicinal composition has the effects of dispelling the effects of alcohol and protecting liver for mice with acute alcoholism
1 Material
1.1 animals:
kunming mice, SPF grade, 18-22 g, experimental animal license number: SYXK 2018 0008, supplied by runan pharmaceutical group inc, was adapted for one week prior to the experiment.
1.2 drugs, agents
1.2.1 medicaments
Granules obtained in examples 1 and 2 of the present invention;
granules obtained in comparative examples 1 and 2.
1.2.3 mouse dosage
Example 1 granules: 2.925g/kg (high dose), 5.85g/kg (medium dose), 11.7g/kg (low dose);
example 2 granules: 5.85g/kg
Comparative example 1 granules: 5.85g/kg;
comparative example 2 oral liquid: 10ml/kg.
2. Method of
2.1 method of Forming mold
80 mice were randomly assigned to a blank group, a model group, three dose groups of example 1 (high, medium, low), example 2 group, comparative example 1 group, comparative example 2 group, and 10 mice per group.
After each group of mice is fasted for 12 hours, the blank group and the model group are subjected to gastric lavage to administer physiological saline, and the other groups of mice are respectively subjected to gastric lavage to administer corresponding medicaments; after 30min of administration, all groups of mice except the blank group are subjected to gastric lavage according to the weight of 0.14ml/10g, and 56 degrees Beijing red star Erguotou white spirit is administered.
2.2 detection index
2.2.1 detection of ethanol content in blood and ALT and AST Activity
After the white spirit is filled into the stomach for 30min, the eyeballs of the mice are removed to obtain blood, serum is separated, and the ethanol content and ALT and AST activities are measured.
2.2.2 detection of ADH and SOD Activity in liver tissue
After the white spirit is infused into the stomach for 30min, each group of mice is anesthetized, liver tissues are taken, homogenized, centrifuged, supernatant is taken, and ADH and SOD activities are detected.
2.3 statistical treatment
Statistical analysis of the obtained data using SPSS22.0 software for metering the dataRepresentation, ratioAnd a one-factor analysis of variance is adopted. With P<A difference of 0.05 is statistically significant.
3. Results and conclusions
3.1 Effect on ethanol content in blood of mice with acute alcoholism
Compared with the model group, the serum of the mice in each administration group has obviously reduced ethanol content, and the difference has statistical significance (P <0.05, P < 0.01); the serum ethanol content was higher in the mice of comparative example 1, group 2 compared to the low dose group of example 1, the difference being statistically significant (P <0.05, P < 0.01).
Table 3 comparison of ethanol content in serum of mice of each groupn＝10)
Note that: in contrast to the set of models, △ P＜0.05， # P＜0.01。
in contrast to the low dose group of example 1, & P＜0.05， ￥ P＜0.01。
3.2 Effect on acute poisoning mouse ADH and SOD Activity
Compared with a blank group, the model group has obviously reduced ADH and SOD activities, and the difference has statistical significance (P < 0.01); compared with the model group, the ADH and SOD activities of each administration group are obviously increased, and the differences are statistically significant (P <0.05, P < 0.01); the comparative example 2 group showed less ADH and SOD activity than the example 1 low dose group, and the difference was statistically significant (P < 0.05).
Table 4 comparison of liver tissue ADH and SOD Activity of mice of each groupn＝20)/>
Note that: in contrast to the blank set of the samples, @ P＜0.05， * P＜0.01；
in contrast to the set of models, △ P＜0.05， # P＜0.01；
in contrast to the low dose group of example 1, & P＜0.05， ￥ P＜0.01。
3.3 Effect on serum ALT and AST activity in mice with acute alcoholism
Compared with the blank group, the activity of ALT and AST of the model group is obviously increased, and the difference has statistical significance (P < 0.01); compared with the model group, the activity of ALT and AST of each administration group is obviously reduced, and the difference has statistical significance (P < 0.01); the ALT and AST activities were higher in the comparative examples 1 and 2 compared to the low dose group of example 1, and the differences were statistically significant (P <0.05, P < 0.01).
TABLE 5 comparison of liver tissue ALT and AST Activity of mice of each groupn＝20)
Note that: in contrast to the blank set of the samples, @ P＜0.05， * P＜0.01；
in contrast to the set of models, △ P＜0.05， # P＜0.01；
in contrast to the low dose group of example 1, & P＜0.05， ￥ P＜0.01。
ADH is a main enzyme participating in ethanol metabolism in vivo, and can oxidize ethanol into acetaldehyde in the presence of oxidized coenzyme, so that the mass concentration of ethanol is obviously reduced, and the alcohol dispelling effect is exerted; SOD is an important free radical scavenger in vivo; ALT and AST are mainly present in the liver cytoplasm, and when the liver is damaged, transaminase in serum is significantly increased.
The traditional Chinese medicine composition has obvious anti-alcohol effect, can accelerate ethanol metabolism by increasing ADH activity, can also increase SOD activity, and reduces damage to liver.
Claims (5)
1. Use of a Chinese medicinal composition prepared from Notopterygii rhizoma, radix Angelicae Pubescentis, poria, radix Saposhnikoviae, herba Schizonepetae, rhizoma Ligustici Chuanxiong, radix Platycodi, bupleuri radix, radix Peucedani, fructus Aurantii, and Glycyrrhrizae radix in preparing medicine for preventing alcoholic brain injury; the traditional Chinese medicine composition is prepared from the following raw materials:
5-30 parts of schizonepeta, 5-30 parts of divaricate saposhnikovia root, and 5-30 parts of notopterygium root
Radix angelicae pubescentis 5-30 parts by weight of radix bupleuri 3-25 parts by weight of radix peucedani 3-25 parts by weight
Ligusticum wallichii 5-30 parts by weight of bitter orange 3-25 parts by weight of poria cocos 5-30 parts by weight
3-25 parts of platycodon grandiflorum and 1-10 parts of liquorice.
2. The use according to claim 1, wherein the Chinese medicinal composition is prepared from the following raw materials:
10-20 parts of schizonepeta, 10-20 parts of divaricate saposhnikovia root, and 10-20 parts of notopterygium root
Radix angelicae pubescentis 10-20 parts by weight of radix bupleuri 3-20 parts by weight of radix peucedani 3-20 parts by weight
10-20 parts of ligusticum wallichii, 3-20 parts of fructus aurantii, and 10-25 parts of poria cocos
3-20 parts of platycodon grandiflorum and 1-8 parts of liquorice.
3. The use according to claim 2, wherein the Chinese medicinal composition is prepared from the following raw materials:
herba schizonepetae 15 weight parts, ledebouriella root 15 weight parts and notopterygium root 15 weight parts
Radix angelicae pubescentis 15 parts by weight, radix bupleuri 15 parts by weight and radix peucedani 15 parts by weight
Rhizoma Ligustici Chuanxiong 15 weight parts fructus Aurantii 15 weight parts Poria 15 weight parts
15 parts of platycodon grandiflorum and 5 parts of liquorice.
4. The use according to any one of claims 1 to 3, wherein the method of preparing the traditional Chinese medicine composition comprises the steps of:
step A: extracting volatile oil from herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong and fructus Aurantii by distillation, and collecting the residue after distillation and distilled rhizoma Ligustici Chuanxiong and fructus Aurantii water solution;
and (B) step (B): c, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii into 10-40% ethanol solution for later use;
step C: mixing Poria, distilled rhizoma Ligustici Chuanxiong and fructus Aurantii residue obtained in step A, percolating with ethanol solution obtained in step B, and collecting percolate;
step D: decocting bupleuri radix, radix Platycodi, glycyrrhrizae radix, distilled herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis and radix Peucedani residue in water, and concentrating the decoction;
step E: mixing the percolate obtained in the step C and the decoction obtained in the step D, concentrating, and adding the volatile oil obtained in the step A to obtain the final product.
5. The method according to claim 4, wherein the step B is to prepare the distilled aqueous solution of Ligusticum wallichii and fructus Aurantii into 15-30% ethanol solution for later use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010740135.7A CN113995788B (en) | 2020-07-28 | 2020-07-28 | Liver protection composition and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010740135.7A CN113995788B (en) | 2020-07-28 | 2020-07-28 | Liver protection composition and preparation process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113995788A CN113995788A (en) | 2022-02-01 |
| CN113995788B true CN113995788B (en) | 2023-11-24 |
Family
ID=79920603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010740135.7A Active CN113995788B (en) | 2020-07-28 | 2020-07-28 | Liver protection composition and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113995788B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114073731A (en) * | 2020-08-14 | 2022-02-22 | 鲁南制药集团股份有限公司 | A Chinese medicinal composition for treating abdominal pain and diarrhea |
| CN115501278A (en) * | 2022-02-08 | 2022-12-23 | 山东新时代药业有限公司 | Application of Jingfang composition in preparation of medicine or health-care product for preventing or improving chronic fatigue syndrome |
| CN115487238A (en) * | 2022-04-27 | 2022-12-20 | 山东新时代药业有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for preventing or treating hepatic fibrosis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497224A (en) * | 2015-12-22 | 2016-04-20 | 河南牧业经济学院 | Anti-viral traditional Chinese medicine micro-ecological preparation for livestock and poultry and preparation method of anti-viral traditional Chinese medicine micro-ecological preparation |
-
2020
- 2020-07-28 CN CN202010740135.7A patent/CN113995788B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497224A (en) * | 2015-12-22 | 2016-04-20 | 河南牧业经济学院 | Anti-viral traditional Chinese medicine micro-ecological preparation for livestock and poultry and preparation method of anti-viral traditional Chinese medicine micro-ecological preparation |
Non-Patent Citations (4)
| Title |
|---|
| 彭成 等."中国临床药物大辞典 中药成方制剂卷 上"，彭成 等，第1084-1085页，中国医药科技出版社，第1版.《中国临床药物大辞典 中药成方制剂卷 上》.中国医药科技出版社,2018,(第1版),第1084-1085页. * |
| 荆防败毒散加减对急性酒精中毒小鼠的解酒作用;童妍 等;《中国实验方剂杂志》;20111130;第17卷(第21期);第221-223页 * |
| 荆防败毒散药效学研究;张奎 等;《河南中医》;20090630;第29卷(第6期);第601-602页 * |
| 败毒散源流与古今临床应用研究;魏英俊 等;《西部中医药》;20151231;第28卷(第3期);第50-53页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113995788A (en) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113995788B (en) | Liver protection composition and preparation process thereof | |
| CN101933991B (en) | Analgesic and anti-inflammatory medicament and preparation method thereof | |
| CN111973721A (en) | Pharmaceutical composition for improving sleep and preparation method and application thereof | |
| CN102335385B (en) | Chinese medicinal composition for easing qi, stimulating appetite, removing stagnation and relieving pains, and preparation method thereof | |
| CN110973625A (en) | Liver-protecting and sobering-up composition based on fructus cannabis and preparation method and application thereof | |
| CN103142916A (en) | Medicament for preventing and treating senile dementia and preparation method thereof | |
| CN104435567A (en) | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout | |
| CN101745042B (en) | Composition with effects of relieving alcoholism and protecting liver and preparation method thereof | |
| CN101317900B (en) | Chinese medicinal composition for preventing and controlling alcoholic liver damnification and preparation method thereof | |
| CN105343660A (en) | Traditional Chinese medicinal preparation for treating peripheral vertigo and preparation method of traditional Chinese medicinal preparation | |
| CN113995787A (en) | Composition with function of dispelling effects of alcohol and preparation method thereof | |
| CN1182864C (en) | Medicine for vascular denmentia disease and preparation method | |
| CN100486621C (en) | Chinese medicinal composition for treating hemilateral headache and its preparation method | |
| CN112439038A (en) | Medicine for quickly improving sleep | |
| CN104338017A (en) | Pharmaceutical composition with sleep improvement effect, preparation method and application thereof | |
| CN111388604B (en) | Traditional Chinese medicine composition for treating migraine and preparation method thereof | |
| CN115737747B (en) | Traditional Chinese medicine composition for improving memory and preventing and treating senile dementia and application thereof | |
| CN103623096B (en) | Hemiplegia xingnao zaizao pill and preparation method thereof | |
| CN115624604B (en) | Traditional Chinese medicine composition for treating climacteric depression and preparation method and application thereof | |
| WO2003094941A1 (en) | Traditional chinese pharmaceutical formulation for treatment of paradentosis, process for preparation and use thereof | |
| CN105770205A (en) | Pharmaceutical composition containing felodipine and capable of treating hypertension and preparation method thereof | |
| CN105796729B (en) | Blood-nourishing and brain-refreshing soft capsule and preparation method thereof | |
| CN113599438A (en) | Traditional Chinese medicine composition for treating children amnesia and preparation method and application thereof | |
| CN115350226A (en) | Traditional Chinese medicine mixture for treating postpartum depression and application thereof | |
| CN118286356A (en) | Traditional Chinese medicine composition for treating headache and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |